CSIMarket Company Name, Ticker, Suppliers, else..
 
Briacell Therapeutics Corp   (NASDAQ: BCTX)
Other Ticker:  
 
 
Price: $3.8400 $0.39 11.304%
Day's High: $3.8904 Week Perf: 11.3 %
Day's Low: $ 3.45 30 Day Perf: 1.59 %
Volume (M): 62 52 Wk High: $ 45.45
Volume (M$): $ 238 52 Wk Avg: $15.29
Open: $3.73 52 Wk Low: $0.43



 Market Capitalization (Millions $) 61
 Shares Outstanding (Millions) 16
 Employees 34
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 0

Briacell Therapeutics Corp
BriaCell Therapeutics Corp is a clinical-stage biotechnology company that focuses on the development of targeted immunotherapy treatments for various types of cancer. The company's lead product candidate is Bria-IMT, which is a genetically engineered whole-cell therapy that targets breast cancer. Bria-IMT is designed to stimulate the patient's immune system to recognize and attack cancer cells. The company is currently conducting several clinical trials to evaluate the safety and efficacy of Bria-IMT in different cancer indications. BriaCell Therapeutics aims to provide innovative and personalized treatment options for patients with advanced breast cancer and potentially other types of solid tumors.


   Company Address: 235 15th Street West Vancouver 0 BC
   Company Phone Number: 921-1810   Stock Exchange / Ticker: NASDAQ BCTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.5%    
JNJ   -2.92%    
LLY   -1.96%    
MRK   -0.69%    
PFE   -3.45%    
TAK   -0.2%    
• View Complete Report
   



Shares

BriaCell Takes Bold Steps Forward with 15:1 Share Consolidation and Breakthroughs in Personalized Breast Cancer Treatment,

Published Mon, Jan 27 2025 11:42 PM UTC

BriaCell Therapeutics Moves Forward with 15:1 Share Consolidation Amid Promising Breast Cancer DevelopmentsBriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSX: BCT), a forward-thinking clinical-stage biotechnology company, has announced the completion of a significant share consolidation aimed at enhancing its compliance with the listing requirements of the Nasdaq Capital ...
Clinical Study

BriaCells Bria-OTS Pioneering a Personalized Approach in Metastatic Breast Cancer Treatment,

Published Thu, Nov 21 2024 12:50 PM UTC

Revolutionary Steps in Metastatic Breast Cancer Treatment: BriaCell s Innovative Bria-OTS Study Begins In a significant breakthrough for metastatic breast cancer treatment, BriaCell Therapeutics Corp., a dynamic force in the biotech industry, has announced the dosing of the first patient in its groundbreaking Phase 1/2 study. This milestone marks the debut of Bria-OTS, BriaC...
Clinical Study

BriaCell Therapeutics Charting a Bold Course in the Battle Against Metastatic Breast Cancer in Phase 3 Trials,

Published Tue, Oct 15 2024 11:51 AM UTC

Navigating New Frontiers in Metastatic Breast Cancer: BriaCell s Pioneering Phase 3 Clinical UpdateIn a transformative moment for oncological therapeutics, BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSX: BCT) has announced a significant clinical engagement update regarding its pivotal Phase 3 study involving Bria-IMT, an innovative immunotherapy designed for patients...
Briacell Therapeutics Corp

Briacell Therapeutics Corp Faces Struggles in Fiscal Third Quarter of 2024 with Declining Performance



Author:
In the midst of financial uncertainties, BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company specializing in immunotherapies, has announced the commencement of patient enrollment for a groundbreaking Phase 1/2 clinical study. This study aims to evaluate the safety and efficacy of Bria-OTS, an off-the-shelf personalized immunotherapy, both as a monotherapy and in combination with the PD-1 inhibitor tislelizumab, in the treatment of advanced metastatic breast cancer.
The recent financial results of BriaCell Therapeutics have left investors concerned. Consultants in the Major Pharmaceutical Preparations sector have been closely monitoring the company's performance in the third quarter of 2024. The operating deficit for this period stands at a concerning $-9.229648 million, significantly worse off compared to the $-5.677029 million reported in the same quarter of 2023. Additionally, the company has yet to report any revenue, greatly adding to investor anxiety.
Announcement

BriaCell Takes Bold Step Towards Advanced Metastatic Breast Cancer Therapy with Innov...

Published Thu, May 30 2024 12:01 PM UTC

The fight against advanced metastatic breast cancer has taken a significant leap forward as BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), an innovative clinical-stage biotechnology company specializing in novel immunotherapies, commences patient enrollment in a pioneering Phase 1/2 clinical study. This trial seeks to evaluate the safety and efficacy of Bria-O...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com